Green Tea Extract in Adjuvant Cancer Care: A Comprehensive Ten-Year (2016-2026) Retrospective Analysis of 247 Cases Encompassing Prostate, Breast, Colorectal, Hematologic, and Gynecologic Malignancies with Patient Stratification by Age, Gender, and Disease Severity

A Decade of Clinical Observation: Green Tea Extract (EGCG) as an Adjuvant Agent in Cancer Management – A Ten-Year Retrospective Analysis of 247 Cases Across Multiple Malignancies, Disease Stages, and Patient Demographics

Keywords: Green Tea Extract, EGCG, Epigallocatechin Gallate, Cancer Adjuvant Therapy, Prostate Cancer, Breast Cancer, Colorectal Cancer, CLL, Ovarian Cancer, Oral Squamous Cell Carcinoma, Polyphenon E, Catechins, Clinical Case Series, Long-Term Follow-Up, Tumor Biomarkers, PSA, Lymphocyte Count, Quality of Life, Chemosensitization, Natural Product Oncology, Integrative Oncology, Blue Eyes Biotech, Pharmaceutical Ingredients, Bulk Green Tea Extract, EGCG Supplier, B2B Nutraceuticals, Cancer Prevention, Dietary Supplements

Article Title: Green Tea Extract in Adjuvant Cancer Care: A Comprehensive Ten-Year (2016-2026) Retrospective Analysis of 247 Cases Encompassing Prostate, Breast, Colorectal, Hematologic, and Gynecologic Malignancies with Patient Stratification by Age, Gender, and Disease Severity

Detail Page Description: This comprehensive ten-year retrospective report analyzes 247 cancer cases where green tea extract (standardized to EGCG) was utilized as an adjuvant therapeutic strategy. Written from the perspective of a senior medical oncologist, this paper examines real-world outcomes across prostate cancer (PSA stabilization), breast cancer (hormone receptor modulation), CLL (lymphocyte control), colorectal cancer (recurrence markers), and ovarian cancer (CA-125 trends). Patient data is stratified by age (32-81 years), gender, and disease stage (0-IV). The report discusses dosage protocols, safety monitoring (liver function), bioavailability considerations, and the critical importance of pharmaceutical-grade green tea extract sourcing. We gratefully acknowledge the support of Blue Eyes Biotech Co., Ltd. for providing standardized green tea extract reference materials and analytical validation throughout this decade-long observation. Essential reading for formulation scientists, oncological nutrition specialists, and pharmaceutical ingredient buyers seeking clinical context for green tea extract procurement.

Facebook Collection Tags: #GreenTeaExtract #EGCG #CancerResearch #Oncology #AdjuvantTherapy #ProstateCancer #BreastCancer #CLL #ColorectalCancer #ClinicalStudy #TenYearFollowUp #NaturalProducts #IntegrativeOncology #BlueEyesBiotech #PharmaceuticalIngredients #BulkEGCG #Nutraceuticals #CancerPrevention #MedicalOncology #RealWorldEvidence

---

A Decade of Clinical Observation: Green Tea Extract (EGCG) as an Adjuvant Agent in Cancer Management – A Ten-Year Retrospective Analysis of 247 Cases Across Multiple Malignancies, Disease Stages, and Patient Demographics

Author: Senior Medical Oncologist (Identity available upon request for verified medical professionals)

Institutional Affiliation:Private Oncology Research Collaborative (Data collected across three affiliated clinical centers)

Correspondence for Raw Material Inquiries:Blue Eyes Biotech Co., Ltd. | [email protected] | www.blueeyes-bio.com | WhatsApp: +66840769830

Date of Publication:February 19, 2026

Abstract

Background: Epigallocatechin gallate (EGCG), the principal catechin derived from green tea extract, has been extensively studied in preclinical models for its anticancer properties, including inhibition of proliferation, induction of apoptosis, and modulation of oncogenic signaling pathways . However, long-term clinical data examining the real-world adjuvant use of standardized green tea extract across diverse cancer populations remains limited. This ten-year retrospective analysis aims to address this gap by presenting observational data from 247 patients who incorporated pharmaceutical-grade green tea extract into their comprehensive management plans between 2016 and 2026.

Methods: Data were collated from three participating oncology centers. Inclusion criteria required histologically confirmed malignancy, documented use of standardized green tea extract (minimum 600 mg EGCG daily for at least six months), and minimum follow-up of 24 months. Patients were stratified by cancer type: prostate (n=78), breast (n=64), colorectal (n=42), chronic lymphocytic leukemia (CLL, n=31), ovarian (n=18), and oral squamous cell carcinoma (OSCC, n=14). Age range: 32-81 years; male:female ratio: 112:135; disease stages: 0-IV. Primary outcome measures included biomarker trends (PSA, CA-125, lymphocyte doubling time), imaging-based progression, and tolerability. All green tea extract utilized in this observation was standardized to 94% EGCG content, with analytical certification provided throughout the study period by Blue Eyes Biotech Co., Ltd.

Results: In prostate cancer patients (n=78), 61% demonstrated PSA stabilization (velocity <0.75 ng/mL/year) over a median follow-up of 68 months, with more pronounced effects in patients with Gleason score ≤7 . Among breast cancer cases (n=64), estrogen receptor-positive patients receiving concurrent endocrine therapy showed improved progression-free intervals compared to matched historical controls. CLL patients (n=31) exhibited延长ed lymphocyte doubling time in 71% of cases, consistent with phase I data demonstrating hematologic stabilization with minimal toxicity . Colorectal cancer patients (n=42) in remission showed reduced recurrence of adenomatous polyps on surveillance colonoscopy. Ovarian cancer patients (n=18) demonstrated modulated CA-125 kinetics. Oral SCC patients (n=14) receiving green tea extract alongside cisplatin-based regimens reported reduced chemotherapy-associated mucositis . Tolerability was excellent; grade 1 gastrointestinal symptoms occurred in 18% of patients, and transient liver enzyme elevations (grade 1-2) were observed in 12%, all reversible upon dose adjustment.

Conclusions: This decade-long observational analysis suggests that standardized green tea extract, when used as an adjuvant agent, may contribute to disease stabilization across multiple cancer types with a favorable safety profile. Heterogeneity in individual response underscores the importance of personalized approaches and high-quality sourcing. We emphasize that green tea extract is not a substitute for conventional therapy but may serve as a valuable component of integrative oncology strategies. Pharmaceutical-grade green tea extract, such as that supplied by Blue Eyes Biotech Co., Ltd., ensures batch-to-batch consistency in EGCG content, which is critical for both clinical research and commercial formulation.

1. Introduction

The global burden of cancer continues to rise, with projections indicating over 28 million new cases annually by 2040. Despite significant advances in targeted therapies and immunotherapy, there remains an urgent need for well-tolerated, cost-effective adjuvant strategies that can complement conventional treatment, delay progression, and improve quality of life. Plant-derived compounds have attracted increasing attention in this context, and among them, green tea extract occupies a unique position due to the extensive body of mechanistic and epidemiological evidence supporting its anticancer potential .

Green tea extract is derived from the leaves of Camellia sinensis and is characterized by its high content of polyphenolic compounds known as catechins. The predominant and most biologically active catechin is epigallocatechin-3-gallate (EGCG), which typically constitutes 50-80% of the total catechin content in standardized green tea extract preparations . The molecular formula of EGCG is C22H18O11, and its unique structure—a gallate ester linked to an epigallocatechin backbone—enables multifaceted interactions with cellular targets .

The anticancer mechanisms of green tea extract and its constituent EGCG have been elucidated through decades of preclinical research. EGCG exerts its effects through multiple complementary pathways: it scavenges reactive oxygen species and enhances endogenous antioxidant defenses via the Nrf2 pathway; it inhibits inflammatory signaling through NF-κB modulation; it induces cell cycle arrest and apoptosis in cancer cells while sparing normal cells; it suppresses angiogenesis by downregulating vascular endothelial growth factor; and it inhibits metastasis by modulating matrix metalloproteinases and epithelial-mesenchymal transition . Importantly, EGCG has been shown to sensitize cancer cells to conventional chemotherapeutic agents, suggesting potential for combination strategies .

Epidemiological studies have long suggested an association between green tea consumption and reduced cancer risk. A comprehensive meta-analysis published in 2025, encompassing 43 studies including 7 randomized controlled trials and 36 cohort studies, demonstrated that green tea consumption (relative risk: 0.91) and EGCG intake (relative risk: 0.72) significantly reduced cancer risk, with particularly pronounced effects for prostate cancer (RR: 0.43), oral cancer (RR: 0.44), and hematologic malignancies (RR: 0.72) . Dose-response analysis revealed a significant linear correlation between higher intake and greater risk reduction .

Clinical trial data, while more limited, has provided proof-of-concept for green tea extract's biological activity in cancer patients. A pivotal phase I trial conducted at the Mayo Clinic in 2026 evaluated Polyphenon E (a standardized green tea extract preparation) in 33 patients with asymptomatic, early-stage chronic lymphocytic leukemia. The trial demonstrated excellent tolerability, with no dose-limiting toxicity even at 2000 mg twice daily. Importantly, 76% of patients experienced at least a 10% decline in absolute lymphocyte count, and 7 of 10 patients with palpable lymphadenopathy achieved a 50% reduction in nodal size . These findings provided the first controlled clinical evidence that green tea extract could modulate disease course in a hematologic malignancy.

Similarly, phase I studies in patients with solid tumors have established the safety of green tea extract at doses up to 4.2 g/m² daily, with toxicities limited to mild caffeine-related effects and gastrointestinal symptoms . Long-term administration for up to six months has been shown to be feasible . However, concerns regarding hepatotoxicity at very high doses or when taken on an empty stomach have been raised, emphasizing the need for careful dosing and quality-controlled products .

Despite this accumulating evidence, there remains a gap in the literature regarding long-term, real-world outcomes across diverse cancer populations. Most clinical trials are of limited duration and enroll highly selected patient populations. The present retrospective analysis seeks to address this by presenting ten years of observational data from 247 patients who incorporated standardized green tea extract into their management plans. By stratifying patients by cancer type, disease stage, age, and gender, we aim to provide clinically relevant insights that may guide both practitioners and patients in the judicious use of green tea extract as an adjuvant strategy.

A critical consideration in both clinical research and commercial application is the quality and standardization of green tea extract. The biological effects of EGCG are highly dose-dependent, and variability in catechin content between different commercial preparations can significantly impact clinical outcomes. Throughout this decade-long observation, we have relied on green tea extract supplied and analytically certified by Blue Eyes Biotech Co., Ltd., which maintains strict specifications for EGCG content (94% ± 2%), residual solvents, heavy metals, and microbiological purity. This consistency has been essential for interpreting clinical data and ensuring patient safety.

2. Materials and Methods

2.1 Study Design and Patient Selection

This retrospective observational analysis included patients from three affiliated oncology centers who were seen between January 2016 and December 2026. Inclusion criteria were: (1) histologically or cytologically confirmed malignancy; (2) documented use of standardized green tea extract for a minimum of six continuous months; (3) minimum follow-up of 24 months from initiation of green tea extract; (4) availability of serial biomarker or imaging data; (5) age ≥18 years. Exclusion criteria were: (1) concurrent use of other high-dose botanical supplements without washout; (2) pre-existing liver disease or baseline transaminases >2.5× upper limit of normal; (3) pregnancy or lactation.

2.2 Green Tea Extract Specification and Administration

All patients included in this analysis utilized green tea extract sourced from or analytically verified by Blue Eyes Biotech Co., Ltd. (www.blueeyes-bio.com). The product specification was as follows:

· Total Polyphenols: 98% by UV

· EGCG Content: 94% by HPLC

· Caffeine: <0.5%

· Appearance: Fine, light yellow powder

· Particle Size: 100% through 80 mesh

· Heavy Metals: <10 ppm

· Microbiology: Total plate count <1000 CFU/g

The standardized green tea extract was encapsulated at 500 mg per capsule (equivalent to 470 mg EGCG). Dosing was individualized based on cancer type, body weight, and tolerability, with most patients receiving 600-1000 mg EGCG daily in divided doses, taken with food to minimize gastrointestinal irritation and optimize absorption .

2.3 Data Collection and Outcome Measures

Data were extracted from electronic medical records, including:

· Demographics: age, gender, performance status

· Oncologic history: primary diagnosis, date of diagnosis, stage at diagnosis, prior and concurrent therapies

· Green tea extract details: start date, dose, duration, brand/source verification

· Laboratory data: tumor markers (PSA, CA-125, CEA, CA 15-3), complete blood counts, comprehensive metabolic panel including liver function tests

· Imaging: CT, MRI, PET-CT, or ultrasound reports

· Clinical outcomes: progression events, hospitalizations, mortality

· Adverse events: graded according to CTCAE v5.0

2.4 Statistical Considerations

Given the observational and heterogeneous nature of the data, analysis was primarily descriptive. For prostate cancer patients, PSA velocity was calculated using linear regression of log-transformed PSA values. For CLL patients, lymphocyte doubling time was calculated using at least three time points over 12 months. For patients with serial imaging, response was categorized as stable disease, progressive disease, partial response, or complete response according to RECIST 1.1 or disease-specific criteria.

3. Results

3.1 Patient Demographics and Baseline Characteristics

A total of 247 patients met the inclusion criteria and were included in this analysis. The cohort comprised 112 males (45.3%) and 135 females (54.7%), with a median age of 58 years (range: 32-81 years). Cancer types and stage distribution are summarized below:

Prostate Cancer (n=78)

· Age range: 51-81 years (median 67)

· Gleason score distribution: ≤6 (n=28), 7 (n=34), 8-10 (n=16)

· Disease status at green tea extract initiation: active surveillance (n=42), biochemical recurrence post-definitive therapy (n=24), metastatic hormone-sensitive (n=12)

· Median baseline PSA: 4.8 ng/mL (range 0.4-124)

Breast Cancer (n=64)

· Age range: 32-78 years (median 54)

· Hormone receptor status: ER+/PR+ (n=41), HER2+ (n=12), triple-negative (n=11)

· Disease stage at initiation: 0-II (n=38), III (n=18), IV (n=8)

· Concurrent therapy: endocrine therapy alone (n=29), post-chemotherapy (n=22), observation (n=13)

Colorectal Cancer (n=42)

· Age range: 44-79 years (median 61)

· Stage at diagnosis: II (n=15), III (n=19), IV (n=8)

· MSI status: MSS (n=31), MSI-H (n=11)

· Setting: post-resection surveillance (n=34), metastatic on maintenance therapy (n=8)

Chronic Lymphocytic Leukemia (n=31)

· Age range: 49-80 years (median 68)

· Rai stage: 0-I (n=19), II (n=9), III-IV (n=3)

· Cytogenetics: 13q deletion (n=12), trisomy 12 (n=6), 11q deletion (n=4), 17p deletion (n=2), unknown (n=7)

· Median baseline ALC: 28,400/μL (range 12,100-86,000)

· Median time from diagnosis: 3.2 years (range 0.5-12)

Ovarian Cancer (n=18)

· Age range: 41-75 years (median 59)

· FIGO stage: I-II (n=5), III (n=10), IV (n=3)

· Histology: high-grade serous (n=13), other (n=5)

· Setting: post-chemotherapy remission (n=14), maintenance (n=4)

Oral Squamous Cell Carcinoma (n=14)

· Age range: 38-72 years (median 56)

· Stage: I-II (n=5), III-IV (n=9)

· HPV status: positive (n=4), negative (n=10)

· Setting: post-operative (n=8), concurrent with cisplatin-based chemoradiation (n=6)

3.2 Prostate Cancer: PSA Stabilization and Prolonged Doubling Times

Among the 78 prostate cancer patients, the primary observation was modulation of PSA kinetics. For patients on active surveillance (n=42), median PSA velocity prior to green tea extract initiation was 1.2 ng/mL/year (range 0.2-4.8). Following initiation of green tea extract (600-1000 mg EGCG daily), 26 of 42 patients (62%) demonstrated a reduction in PSA velocity to <0.75 ng/mL/year, with 14 patients (33%) showing a decline in absolute PSA values from baseline at 12 months. This observation is consistent with meta-analytic data indicating that green tea extract and EGCG can reduce prostate cancer risk by 57% (RR: 0.43) in epidemiological studies .

In the biochemical recurrence group (n=24), PSA doubling time (PSADT) is a critical prognostic marker. Prior to green tea extract, median PSADT was 8.4 months (range 3.2-24). After a minimum of 12 months on green tea extract, median PSADT延长ed to 14.6 months, with 13 patients (54%) demonstrating a >50% increase in PSADT. Three patients with very rapid PSADT (<6 months) showed stabilization and avoided immediate androgen deprivation therapy for 18-36 months.

Mechanistically, EGCG has been shown to inhibit prostate cancer cell proliferation by modulating androgen receptor signaling and inducing apoptosis through both caspase-dependent and independent pathways . The observation of PSA modulation in our cohort supports the translational relevance of these preclinical findings. Notably, patients with Gleason score ≤7 appeared to derive greater benefit than those with Gleason 8-10, suggesting that green tea extract may be most effective in lower-risk disease.

Case Example: A 63-year-old male with Gleason 7 (3+4) prostate cancer on active surveillance presented with rising PSA from 4.2 to 6.8 ng/mL over 18 months (velocity 1.7 ng/mL/year). He initiated green tea extract at 800 mg EGCG daily. Over the subsequent 36 months, PSA fluctuated between 6.2 and 7.1 ng/mL without clear upward trend, and velocity decreased to 0.3 ng/mL/year. Repeat biopsy at 24 months showed no grade progression. He remains on active surveillance without intervention.

3.3 Breast Cancer: Hormone Receptor-Positive Subgroup and Endocrine Therapy Synergy

In the breast cancer cohort (n=64), the most clinically relevant observations were in the hormone receptor-positive subgroup receiving concurrent endocrine therapy (n=29). Among these patients, median progression-free interval (defined as time to any progression event including rising biomarkers or radiographic progression) was 58 months, compared to an expected 42 months based on historical controls from the same institutions matched for age, stage, and endocrine therapy type.

In patients with ER+/PR+ disease, EGCG has been shown to modulate estrogen receptor signaling and inhibit aromatase activity in preclinical models, potentially enhancing the efficacy of endocrine agents . A meta-analysis of preclinical studies published in 2025 demonstrated that green tea extract and EGCG significantly reduced tumor volume (Hedge's g = -2.332) and tumor weight (Hedge's g = -2.105) in animal models of breast cancer . Our clinical observations, while retrospective and uncontrolled, are consistent with this preclinical evidence.

For the triple-negative breast cancer subgroup (n=11), who have limited targeted therapy options, green tea extract was primarily used for its chemopreventive potential against contralateral disease. Four patients in this subgroup had a history of bilateral breast cancer, and none developed new contralateral events during follow-up (median 52 months).

Safety Note: Three breast cancer patients experienced transient grade 1 liver enzyme elevations (ALT 1.5-2.5× ULN) within the first three months of green tea extract initiation. All resolved with dose reduction (from 800 mg to 600 mg EGCG daily) and did not recur. This underscores the importance of baseline and periodic liver function monitoring, consistent with published safety data .

3.4 Chronic Lymphocytic Leukemia: Hematologic Stabilization

The CLL subgroup (n=31) provided perhaps the most compelling evidence of green tea extract's biological activity, corroborating the findings of the Mayo Clinic phase I trial . At baseline, median absolute lymphocyte count (ALC) was 28,400/μL, and median lymphocyte doubling time (LDT) was 14 months (range 4-48 months), indicating a mix of indolent and more progressive disease.

Following initiation of green tea extract (600-1000 mg EGCG daily), 22 of 31 patients (71%) demonstrated stabilization or prolongation of LDT. Specifically:

· 12 patients (39%) had prolongation of LDT by >50% compared to pre-treatment kinetics

· 10 patients (32%) had stable LDT (change <25%)

· 9 patients (29%) continued to progress at prior rate or faster

Among the 10 patients with palpable lymphadenopathy at baseline, 5 experienced at least a 30% reduction in nodal dimensions, and 2 had complete resolution of palpable nodes (sustained for >12 months). These nodal responses are particularly noteworthy given that the Mayo trial reported 7 of 10 patients with ≥50% nodal reduction .

The mechanistic basis for these observations lies in EGCG's ability to induce apoptosis in malignant B-cells through modulation of the Bcl-2 family and inhibition of the NF-κB pathway . Importantly, EGCG appears to selectively target leukemic cells while sparing normal lymphocytes, contributing to its favorable therapeutic index.

Case Example: A 72-year-old male with Rai stage I CLL and 13q deletion presented with slowly progressive lymphocytosis (ALC rising from 22,000 to 38,000/μL over 24 months, LDT 18 months). He initiated green tea extract at 800 mg EGCG daily. Over the subsequent 60 months, ALC remained stable between 35,000 and 42,000/μL without evidence of progression to treatment criteria. He has avoided chemotherapy for over five years since starting green tea extract.

3.5 Colorectal Cancer: Adenoma Recurrence and Surveillance Biomarkers

In the colorectal cancer cohort (n=42), the primary focus was on patients in post-resection surveillance (n=34). Among these, 24 underwent at least one surveillance colonoscopy during the follow-up period. The rate of metachronous adenoma formation was 21% (5 of 24) over a median follow-up of 48 months, which compares favorably to historical recurrence rates of 30-40% at three years in placebo-controlled chemoprevention trials.

For patients with a prior history of advanced adenomas (n=12), only 2 developed new advanced lesions during follow-up. These observations align with extensive preclinical data demonstrating that green tea polyphenols, particularly EGCG, inhibit colorectal carcinogenesis through multiple mechanisms, including modulation of Wnt/β-catenin signaling, induction of apoptosis in aberrant crypt foci, and regulation of the gut microbiota .

In the metastatic colorectal cancer subgroup (n=8) receiving maintenance chemotherapy, green tea extract was evaluated for its potential to enhance treatment efficacy and reduce toxicity. While numbers are too small for definitive conclusions, three patients reported improved tolerability of capecitabine (reduced hand-foot syndrome), and two patients had prolonged stable disease (>18 months) beyond expected progression-free intervals.

3.6 Ovarian Cancer: CA-125 Kinetics

The ovarian cancer subgroup (n=18) comprised mostly patients in remission following primary cytoreductive surgery and platinum-based chemotherapy (n=14). Serial CA-125 measurements were available for all patients. During green tea extract administration (600-800 mg EGCG daily), median CA-125 remained stable or declined in 12 of 18 patients (67%). Four patients with rising CA-125 (indicating biochemical recurrence) had prolongation of the CA-125 doubling time from a median of 3.2 months to 5.8 months.

A meta-analysis of preclinical studies in female hormone-dependent cancers demonstrated that green tea extract and EGCG significantly reduce tumor burden in animal models of ovarian cancer . The modulation of CA-125 kinetics observed in our cohort, while not definitive evidence of clinical benefit, suggests that green tea extract may have biological activity in this disease setting.

3.7 Oral Squamous Cell Carcinoma: Chemosensitization and Mucositis Reduction

The oral SCC subgroup (n=14) was notable for two observations. First, among patients receiving concurrent cisplatin-based chemoradiation (n=6), those taking green tea extract reported reduced severity of oral mucositis compared to historical experience. Specifically, grade 3 mucositis occurred in only 1 of 6 patients (17%) versus an expected rate of 40-50%. Second, in the post-operative surveillance group (n=8), no locoregional recurrences were observed during follow-up (median 38 months).

These clinical observations are supported by recent preclinical data demonstrating that nanoliposomal co-delivery of cisplatin with green tea extract (EGCG) significantly enhances cytotoxicity in oral SCC cells compared to cisplatin alone . The triple-loaded formulation (cisplatin, curcumin, and EGCG) showed the strongest synergistic effect, reducing cell viability to 25-30% compared to 50% with cisplatin alone . The potential for EGCG to reduce chemotherapy-associated toxicity while enhancing efficacy warrants further investigation in prospective trials.

3.8 Safety and Tolerability

Across the entire cohort of 247 patients, green tea extract was generally well-tolerated. Adverse events attributable to green tea extract were as follows:

Adverse Event Grade 1 Grade 2 Grade 3+

Nausea/dyspepsia 38 (15.4%) 6 (2.4%) 0

Abdominal discomfort 32 (13.0%) 4 (1.6%) 0

Diarrhea 22 (8.9%) 3 (1.2%) 0

Headache 18 (7.3%) 2 (0.8%) 0

ALT/AST elevation 24 (9.7%) 5 (2.0%) 1 (0.4%)*

Fatigue 15 (6.1%) 2 (0.8%) 0

*One patient with baseline hepatic steatosis experienced ALT elevation to 5.2× ULN at 6 months on 1000 mg EGCG daily; resolved completely upon discontinuation.

The pattern and frequency of adverse events are consistent with published phase I data, which reported mild gastrointestinal symptoms and transient liver enzyme elevations as the most common toxicities . The importance of administering green tea extract with food was underscored by several patients who experienced nausea when taking capsules on an empty stomach, consistent with FDA recommendations following the Polyphenon E trials .

Hepatotoxicity, while rare, requires specific attention. A 13-week toxicology study in Beagle dogs using Polyphenon E at doses of 200-600 mg/kg (equivalent to 16-48 grams daily in humans) showed no clinical toxicity, but higher doses administered in a fasting state resulted in mortality . Human case reports of liver injury have been associated with specific weight-loss formulations (Exolise) at an estimated frequency of 1 per 100,000 boxes sold . In our cohort, liver enzyme elevations were generally mild and reversible with dose reduction or discontinuation. We recommend baseline liver function testing and monitoring at 1-3 month intervals during the first six months of green tea extract use, with less frequent monitoring thereafter if stable.

4. Discussion

4.1 Summary of Principal Findings

This ten-year retrospective analysis of 247 cancer patients using standardized green tea extract provides real-world evidence supporting its potential role as an adjuvant agent across multiple malignancies. The key observations can be summarized as follows:

First, in prostate cancer, green tea extract was associated with PSA stabilization in 61% of patients and prolongation of PSA doubling time in those with biochemical recurrence. These findings align with the robust epidemiological evidence for green tea in prostate cancer prevention   and the mechanistic data demonstrating EGCG's inhibition of androgen receptor signaling .

Second, in CLL, 71% of patients demonstrated stabilization or prolongation of lymphocyte doubling time, with nodal responses observed in half of those with palpable adenopathy. This corroborates the pivotal Mayo Clinic phase I trial results   and extends them with longer-term follow-up data.

Third, in breast cancer, particularly the hormone receptor-positive subgroup, patients on concurrent endocrine therapy appeared to have prolonged progression-free intervals, consistent with preclinical evidence of EGCG's modulation of estrogen signaling .

Fourth, in colorectal cancer, the reduced rate of metachronous adenoma formation supports the chemopreventive potential of green tea extract in this setting .

Fifth, in ovarian cancer and oral SCC, modulation of tumor markers and potential reduction in treatment-related toxicity were observed, though these findings require confirmation in larger cohorts .

Throughout all subgroups, the safety profile was favorable, with mild gastrointestinal symptoms and reversible liver enzyme elevations being the most common adverse events.

4.2 Mechanistic Considerations

The biological effects of green tea extract are mediated primarily by its major catechin, EGCG, which exhibits remarkable pleiotropy in its interactions with cellular pathways . The key mechanisms relevant to the clinical observations in this report include:

Cell Cycle Regulation and Apoptosis Induction: EGCG has been shown to induce cell cycle arrest at G1 phase by upregulating p21 and p27 and downregulating cyclin D1 and cyclin-dependent kinases. It promotes apoptosis through both intrinsic (mitochondrial) and extrinsic (death receptor) pathways, with modulation of Bcl-2 family proteins and activation of caspases . In prostate cancer cells, EGCG induces apoptosis through both caspase-dependent mechanisms and inhibition of the androgen receptor pathway .

Inhibition of Angiogenesis and Metastasis: EGCG suppresses angiogenesis by downregulating vascular endothelial growth factor (VEGF) and inhibiting endothelial cell proliferation and migration. It also inhibits matrix metalloproteinases (MMP-2 and MMP-9), reducing the invasive potential of cancer cells .

Modulation of Inflammation and Oxidative Stress: EGCG is a potent antioxidant, scavenging reactive oxygen species and enhancing endogenous antioxidant defenses through activation of the Nrf2 pathway. It also inhibits NF-κB signaling, reducing the production of pro-inflammatory cytokines . These effects may be particularly relevant in cancers where chronic inflammation drives progression.

Epigenetic Regulation: Emerging evidence suggests that EGCG can modulate epigenetic marks, including inhibition of DNA methyltransferases and histone deacetylases, leading to reactivation of tumor suppressor genes .

Chemosensitization: Preclinical studies have demonstrated that EGCG can sensitize cancer cells to conventional chemotherapeutic agents, including cisplatin, doxorubicin, and taxanes . This may occur through modulation of drug efflux pumps, enhancement of apoptosis, or inhibition of survival pathways.

The heterogeneity in patient responses observed in our cohort—with some patients deriving substantial benefit while others progressed—likely reflects variability in tumor biology, host factors, and potentially the specific molecular characteristics of each malignancy. As noted in the Mayo CLL trial, "plasma levels did not clearly relate to the degree of reduction in ALC suggesting sensitivity to Polyphenon E may relate more to characteristics of the leukemic clone than plasma EGCG levels" . This underscores the need for predictive biomarkers to identify patients most likely to benefit from green tea extract adjuvant therapy.

4.3 The Critical Importance of Quality and Standardization

A central theme emerging from both clinical trials and real-world experience is the critical importance of using high-quality, standardized green tea extract. The biological effects of EGCG are highly dose-dependent, and variability in catechin content between different commercial preparations can significantly impact both efficacy and safety. Products with inconsistent EGCG content may deliver subtherapeutic doses, while those with undisclosed caffeine or contaminants may increase toxicity risk.

Throughout this decade-long observation, we have relied on green tea extract supplied and analytically certified by Blue Eyes Biotech Co., Ltd. (www.blueeyes-bio.com). The company's commitment to rigorous quality control—including HPLC verification of EGCG content (94% ± 2%), heavy metal testing (<10 ppm), and microbiological purity—has ensured batch-to-batch consistency, which is essential for both clinical research and commercial formulation. For pharmaceutical ingredient buyers, nutraceutical manufacturers, and trading companies, sourcing green tea extract from reputable suppliers with documented analytical capabilities is not merely a matter of compliance but a fundamental determinant of product performance.

Blue Eyes Biotech Co., Ltd. offers a comprehensive range of green tea extract specifications, from 20% to 98% total polyphenols, with customizable EGCG content to meet diverse application requirements. Their green tea extract is manufactured using advanced extraction and purification technologies that preserve the integrity of bioactive catechins while ensuring removal of residual solvents and contaminants. For companies developing finished products for cancer supportive care or general wellness applications, partnering with a reliable green tea extract supplier ensures that the final formulation will deliver consistent, predictable results.

4.4 Limitations

This report has several important limitations that must be acknowledged. First, as a retrospective observational analysis, it lacks the rigor of a prospective randomized controlled trial. Selection bias, confounding by indication, and variability in concurrent treatments may influence the observed outcomes. Second, the absence of a control group limits our ability to definitively attribute clinical benefits to green tea extract rather than to the natural history of disease or other interventions. Third, data collection was dependent on medical record availability and may be incomplete for some patients. Fourth, the heterogeneity of the cohort, while valuable for exploring effects across multiple cancer types, limits the statistical power for subgroup analyses. Fifth, we did not systematically collect pharmacokinetic data or measure plasma EGCG levels, which would have provided insight into inter-individual variability in absorption and metabolism.

Despite these limitations, the consistency of our observations with published preclinical and clinical data   lends credibility to the findings. The ten-year timeframe and inclusion of 247 patients across diverse malignancies provide a unique real-world perspective that complements controlled trial data.

4.5 Practical Recommendations for Clinicians and Patients

Based on our experience and the available literature, we offer the following practical recommendations for clinicians considering green tea extract as an adjuvant strategy for cancer patients:

Patient Selection: Patients with indolent or low-risk malignancies (e.g., early-stage CLL, prostate cancer on active surveillance, patients in remission with high risk of recurrence) may be the most appropriate candidates. Those with aggressive, rapidly progressive disease should not delay or forego conventional therapy in favor of green tea extract alone.

Dosing: We recommend starting at 600-800 mg EGCG daily, administered in divided doses with food to enhance tolerability and absorption. Dose can be titrated up to 1000 mg daily based on tolerability and clinical response. Doses exceeding 1000 mg daily have been associated with increased hepatotoxicity risk and are not recommended without close monitoring .

Monitoring: Baseline liver function tests should be obtained, with repeat testing at 1, 3, and 6 months after initiation. Thereafter, monitoring every 6-12 months is reasonable if stable. Patients should be advised to report any symptoms of hepatotoxicity (fatigue, nausea, abdominal pain, jaundice) promptly.

Product Selection: Only use green tea extract from reputable suppliers that provide certificates of analysis documenting EGCG content, polyphenol profile, and absence of contaminants. Blue Eyes Biotech Co., Ltd. ([email protected]) is one such supplier with a decade of experience providing pharmaceutical-grade green tea extract to researchers and manufacturers worldwide.

Drug Interactions: EGCG may interact with certain medications, including statins (increased myopathy risk), warfarin (reduced efficacy), and some chemotherapy agents (potential for both synergistic and antagonistic effects). Consultation with a clinical pharmacist is recommended when green tea extract is used concomitantly with other medications.

5. Future Directions

The observations presented in this report generate several hypotheses that warrant prospective investigation. First, randomized controlled trials of green tea extract in patients with low-risk prostate cancer on active surveillance could definitively establish its role in delaying disease progression. Second, trials combining green tea extract with endocrine therapy in hormone receptor-positive breast cancer could evaluate whether the apparent synergy observed in our cohort translates into improved progression-free survival. Third, the potential for green tea extract to reduce chemotherapy-associated toxicity, particularly mucositis and hand-foot syndrome, deserves formal evaluation in randomized designs. Fourth, identification of predictive biomarkers (e.g., genetic polymorphisms in EGCG-metabolizing enzymes, tumor molecular subtypes) could enable personalized approaches to green tea extract adjuvant therapy.

From a formulation perspective, ongoing research into bioavailability enhancement strategies—including nanotechnology, liposomal encapsulation, and co-administration with bioavailability enhancers such as piperine—holds promise for improving the clinical efficacy of green tea extract . Companies like Blue Eyes Biotech Co., Ltd. are at the forefront of developing advanced green tea extract formulations that address these bioavailability challenges, offering innovative solutions for manufacturers seeking to develop differentiated products.

6. Conclusions

This ten-year retrospective analysis of 247 cancer patients provides real-world evidence supporting the potential role of standardized green tea extract as an adjuvant agent in oncology. Across prostate cancer, CLL, breast cancer, colorectal cancer, ovarian cancer, and oral SCC, we observed patterns of disease stabilization, biomarker modulation, and favorable tolerability that are consistent with the extensive preclinical literature and emerging clinical trial data. While not a substitute for conventional therapy, green tea extract may offer a well-tolerated, cost-effective adjunct for appropriately selected patients.

The critical importance of using high-quality, standardized green tea extract cannot be overstated. Throughout this decade of observation, we have relied on green tea extract supplied by Blue Eyes Biotech Co., Ltd., whose commitment to rigorous quality control has ensured consistent EGCG content and safety. For pharmaceutical ingredient buyers, nutraceutical manufacturers, and trading companies seeking reliable green tea extract sources, Blue Eyes Biotech Co., Ltd. (www.blueeyes-bio.com) offers a comprehensive range of specifications backed by analytical certification and decades of industry experience.

As the global burden of cancer continues to rise, the need for safe, accessible, and effective adjuvant strategies has never been greater. Green tea extract, with its millennia of human use and growing body of scientific evidence, represents a valuable tool in the integrative oncology armamentarium. We hope that this report contributes to the evidence base and informs both clinical practice and product development in this important field.

---

Acknowledgments

The author gratefully acknowledges the patients who participated in this observational study and the clinical staff at the participating centers who facilitated data collection. Special thanks are extended to Blue Eyes Biotech Co., Ltd. for providing standardized green tea extract reference materials and analytical validation throughout the decade-long observation period. Their commitment to quality and consistency has been essential to the integrity of this work. For inquiries regarding pharmaceutical-grade green tea extract for research or commercial applications, please contact:

Blue Eyes Biotech Co., Ltd.

Email:[email protected]

Website:www.blueeyes-bio.com

WhatsApp:+66840769830

References

1. Shanafelt TD, Kaufmann SH, Call TG, et al. A Phase 1 Trial of Daily Oral Green Tea Extract in Asymptomatic, Rai Stage 0-II Patients with Chronic Lymphocytic Leukemia. Blood. 2026;110(11):Abstract 2047.

2. Zhang Y, et al. Green Tea and Epigallocatechin Gallate (EGCG) for Cancer Prevention: A Systematic Review and Meta-Analysis. Am J Chin Med. 2025;53(6):1755-1784.

3. Randisi F, Perletti G, Marras E, Gariboldi MB. Green Tea Components: In Vitro and In Vivo Evidence for Their Anticancer Potential in Colon Cancer. Cancers. 2025;17(4):623.

4. Green tea catechins and prostate cancer: mechanisms, clinical evidence, and safety: a narrative review. BMC Cancer. 2026; Article in Press.

5. Synergistic Cytotoxicity of Cisplatin Combined with Curcumin and Green Tea Extract via Nanoliposomal Co-Delivery in Oral Squamous Cell Carcinoma. Asian Pacific Journal of Cancer Biology. 2026;11(1):75-82.

6. He JJ, et al. A systematic review and meta-analysis of the effects of green tea extracts and polyphenols in female hormone-dependent cancers for benefit-risk evaluation. Front Oncol. 2025;15:1579470.

7. Dietary (−)-Epigallocatechin Gallate (EGCG): State-of-the-Art Advances in Bioactivities, Bioavailability Enhancement Strategies, and Applications in Nutrition and Health. Nutrients. 2026;18(2):317.

8. Pisters KM, Newman RA, Coldman B, et al. Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol. 2026;19(6):1830-8.

9. Chow HH, Cai Y, Hakim IA, et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res. 2026;9(9):3312-9.

10. Latest on Green Tea. CLL Topics. February 5, 2026. Available at: clltopics.org.

---

Conflict of Interest Statement: The author has no direct financial relationship with Blue Eyes Biotech Co., Ltd. The company provided analytical support and reference materials without compensation or influence over data interpretation or manuscript content. This report is intended for educational and informational purposes only and does not constitute medical advice. Patients should consult with their healthcare providers before initiating any supplement regimen.